(Source: Xencor Inc) MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible for triggering disease activity in asthma and other allergic disorders. The study describes XmAb7195's three distinct mechanisms of action, including a novel mechanism for rapid clearance of IgE. The study supports future studies in human clinical trials. Data will be presented...
↧